Fortress Biotech Return on Equity

Fortress Biotech (FBIO) currently reports a ROE of 64.01%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore Fortress Biotech's ROE history and peer comparisons.

Fortress Biotech's ROE of 64.01% is higher than the Healthcare sector average of 21.67%. That is roughly 195.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Fortress Biotech's current 64.01% should be judged against Healthcare norms (sector average: 21.67%) and against FBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 64.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Fortress Biotech, and consider following FBIO for alerts when major investors trade the stock.

Fortress Biotech is classified in the Healthcare sector. On ROE, it currently shows 64.01% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FBIO with unrelated industries.